Senate passes a “right to try” bill; Harm to patients comes next

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Kelly McBride Folkers
Research associate, Division of Medical Ethics, NYU School of Medicine
Lisa Kearns
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Alison Bateman-House
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.
Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 
Kelly McBride Folkers
Research associate, Division of Medical Ethics, NYU School of Medicine
Lisa Kearns
Senior research associate, Division of Medical Ethics, NYU School of Medicine
Alison Bateman-House
Assistant professor in the Division, co-chair of NYU's Working Group on Compassionate Use and Pre-Approval Access.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login